Core Viewpoint - The company, Gushengtang (02273), has announced a share buyback plan, which is expected to enhance shareholder value and demonstrate confidence in its long-term business prospects [1] Summary by Relevant Sections Share Buyback Authorization - The shareholders approved a resolution at the annual general meeting on June 20, 2025, granting the board the authority to repurchase up to 23.6965 million shares, representing 10% of the total issued shares as of that date [1] Financial Commitment - The board has resolved to exercise the buyback authorization on August 29, 2025, with a maximum expenditure of HKD 300 million for the repurchase [1] Strategic Rationale - The board believes that the proposed share buyback will enhance share value, benefiting shareholders, and reflects confidence in the company's long-term business outlook [1] - The board also stated that the company's financial position is stable, allowing for the buyback while maintaining sufficient financial resources for ongoing business growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （根據開曼群島法律註冊成立的有限公司） （股份代號：2273） 自願性公告 根據購回授權購回股份 本公告乃由固生堂控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體 統稱為「本集團」）自願作出，謹此知會本公司股東（「股東」）及有意投資者本集 團的最新業務發展情況。 根據股東於2025年6月20日舉行的股東週年大會上通過的股東決議案，本公司 董事（「董事」）獲授購回最多23,696,549股本公司股份（「股份」）的一般授權，佔 截至2025年6月20日已發行股份總數的10%（「購回授權」）。 於2025年8月29日，董事會（「董事會」）決議行使購回授權，適時於公開市場購 回股份，總價最多300百萬港元（「建議股份購回」）。建議股份購回於本公告日 期開始，直至下列最早者：(i)本公司下屆股東週年大會結束時，(ii)任何適用法 律或本公司組織章程細則規定本公司須舉行下屆股東週年大會的期限屆滿時， 或(ii ...

Core Viewpoint - The company reported a significant increase in both revenue and profit for the six months ending June 30, 2025, driven primarily by growth in its healthcare solutions segment [1] Financial Performance - Revenue for the period reached 1.495 billion RMB, representing a year-on-year increase of 9.52% [1] - Shareholder profit attributable to the company was 152 million RMB, showing a substantial year-on-year increase of 41.9% [1] - Basic earnings per share were reported at 0.63 RMB [1] - The company proposed an interim dividend of 0.35 HKD per share [1] Revenue Breakdown - Revenue from healthcare solutions increased from 1.345 billion RMB for the six months ending June 30, 2024, to 1.485 billion RMB for the current period, marking a growth of 10.4% [1] - The growth in revenue from healthcare solutions was primarily attributed to the expansion of offline medical institution operations [1]

Core Points - The company, Guoshengtang (02273), reported a mid-term performance for the six months ending June 30, 2025, with revenue of 1.495 billion RMB, representing a year-on-year increase of 9.52% [1] - Shareholder profit attributable to the company was 152 million RMB, showing a significant year-on-year increase of 41.9% [1] - Basic earnings per share were reported at 0.63 RMB, and the company proposed an interim dividend of 0.35 HKD per share [1] Revenue Growth - The increase in revenue was primarily attributed to the growth in income from providing healthcare solutions [1] - Revenue from healthcare solutions rose from 1.345 billion RMB for the six months ending June 30, 2024, to 1.485 billion RMB for the same period in 2025, marking a growth of 10.4% [1] - The growth in revenue from healthcare solutions was mainly driven by the expansion of offline medical institution operations [1]

GUSHENGTANG HOLDINGS LIMITED 固生堂控股有限公司 （根據開曼群島法律註冊成立的有限公司） （「本公司」） – 1 – 2. 提名委員會的成員須不時由董事會委任，並須由不少於三(3)名成員組成， 當中包括至少一名不同性別的董事，其中大多數成員須為符合香港聯合 交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第3.13條載列之獨 立性要求之獨立非執行董事（「獨立非執行董事」）。 3. 董事會須委任董事會主席或一名獨立非執行董事擔任提名委員會主席（「主 席」）一職。 4. 除提名委員會另外委任外，公司秘書（「公司秘書」）須為提名委員會的秘書， 而如公司秘書未克出席，一名提名委員會成員或其代名人須擔任秘書。 5. 提名委員會每年須至少召開一次會議及於必要情況下根據主席要求召開 其他會議。 6. 提名委員會會議須由公司秘書應主席之要求召開。 報告程序 – 2 – 提名委員會職權範圍 （根據本公司董事會於2025年8月29日通過的決議案所採納） 目標 1. 成立提名委員會之目標為協助本公司董事（「董事」）會（「董事會」）物色、 挑選及向董事會推薦適合成為本公司董事的人選，監督評定董事會 ...

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括主席兼執行董事涂志亮先生，非執行董事HUANG Jingsheng先生及劉康華先生，獨立非執行董事王蘭 女士、李鐵先生及仲偉合先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 固生堂控股有限公司 | | 股份代號 | 02273 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 宣派及支付截至2025年6月30日止六個月中期股息及暫停辦理股份過戶登記 | | | 公告日期 | 2025年8月29日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （根據開曼群島法律註冊成立的有限公司） （股份代號：2273） 中期業績公告 截至2025年6月30日止六個月 財務摘要 本集團的收入由截至2024年6月30日止六個月的人民幣1,365.0百萬元增加9.5% 至截至2025年6月30日止六個月的人民幣1,494.9百萬元。 董事會欣然公佈本集團截至2025年6月30日止六個月的未經審核綜合中期業績， 連同於2024年同期的比較數字載列如下。 未經審核中期簡明綜合損益及其他全面收益表 截至2025年6月30日止六個月 | | 附註 | 2025年 | 2024年 | | --- | --- | --- | --- | | | | 人民幣千元 | 人民幣千元 | | | | （未經審核）（未經審核） | | | 收入 | 4 | 1,494,891 | 1,364 ...

Group 1 - The company, Guoshengtang (02273.HK), announced that its board meeting will be held on August 29, 2025, to consider and approve the unaudited interim results for the six months ending June 30, 2025, and to discuss the potential distribution of an interim dividend, if any [1]

香港交易所及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 GUSHENGTANG HOLDINGS LIMITED 固 生 堂 控 股 有 限 公 司 （股份代號：2273） 董事會會議日期 固生堂控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱為「本 集團」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會議將於二零二五年八 月二十九日（星期五）舉行，藉以（其中包括）考慮及批准本集團截至二零二五 年六月三十日止六個月之未經審核中期業績及其刊發，並考慮派發中期股息（如 有）。 承董事會命 GUSHENGTANG HOLDINGS LIMITED 固生堂控股有限公司 董事會主席 涂志亮 香港，二零二五年八月十九日 於本公告日期，本公司董事會包括主席兼執行董事涂志亮先生，非執行董事HUANG Jingsheng 先生及劉康華先生，獨立非執行董事王蘭女士、李鐵先生及仲偉合先生。 （根據開曼群島法律註冊成立的有限公司） ...

Core Viewpoint - The conference on high-quality development of traditional Chinese medicine (TCM) highlighted the strategic layout of Guoshengtang in promoting the internationalization of TCM through "management empowerment + AI technology + products" to establish itself as the leading TCM health brand for the global Chinese community [1] Group 1: Management Expansion - Guoshengtang's acquisition of Singapore's Baozhongtang in March 2024 marks the beginning of its internationalization journey, achieving a revenue growth of 119% year-on-year by July 2025 [2] - The company plans to expand to 30 clinics in Singapore by the end of 2026, leveraging its mature domestic operational model [2] - Guoshengtang employs a multi-faceted strategy for overseas expansion, including self-built flagship stores, strategic partnerships with local TCM institutions, and acquisitions of quality Western medical clinics and hospitals [2] Group 2: AI Technology Deployment - The launch of 10 AI avatars of renowned TCM doctors addresses the shortage of quality TCM talent overseas, facilitating online follow-up consultations [4] - The AI avatars have achieved over 86% consistency in expert simulation, receiving high praise for their diagnostic accuracy and medication rationality [4][5] - The AI technology not only enhances domestic operations but also plays a crucial role in the company's international endeavors, breaking down barriers in the distribution of TCM talent [5] Group 3: Product Internationalization - Guoshengtang has made significant strides in the development of innovative TCM products, with its first self-developed TCM product receiving certification from Singapore's Health Sciences Authority [6] - The company is collaborating with Huaxi Hospital and Baidu to establish a clinical evaluation platform for TCM, aiming to address challenges in real-world data assessment [6] - Guoshengtang has accumulated extensive high-quality TCM data over 10 years, including over 17 million consultation records and 8 million medical records, which supports its innovative drug development efforts [6] Group 4: Future Outlook - The company aims to enhance its research and development of TCM formulations, creating a robust platform for innovative TCM services [7] - By integrating traditional TCM with modern technology, Guoshengtang is making significant progress towards its goal of becoming the global leading TCM brand for the Chinese community [7]